"This would have 92 percent accuracy relative to what we currently have, which is at best 75 percent accuracy," said Dr. Ronald DePinho of Dana-Farber's Belfer Institute for Applied Cancer Science in Massachusetts.
DePinho said the results will make a big impact on how men are tested and treated for prostate cancer, the second most common cancer in men worldwide after lung cancer, killing 254,000 a year.
"The goal is to do this within about a year or maybe a bit longer than that," said DePinho, who has a stake in the company.